论文部分内容阅读
Regenerative liver surgery is the field of research and clinical practice which tries to increase the volume of the future liver remnant prior to resection. Too small liver remnants lead to post-hepatectomy liver failure after extensive resections, a syndrome of portal flow congestion, progressive cholestasis, lack of synthetic function, renal failure, ascites, encephalopathy and ultimately death from infection. What is too small, is not entirely clear, depends on many patient, liver and surgery factors, but is generally between 20-40%. The field of regenerative liver surgery expanded considerably over the last years and has become the favorite playground for surgeons who like to push the limits of resectability of liver tumors. Skeptical and weary oncologists at multidisciplinary tumor boards have become used to the sight of liver surgeons who consider no extent of disease off limits, equipped with a growing armada of eponyms like "portal vein embolisation (PVE)", "portal vein ligation (PVL)", "associating liver partition and PVL for staged hepatectomy (ALPPS)", "associating liver touiquet and PVL for staged hepatectomy (ALTPS)", "partial ALPPS (PALPPS)", "radiofrequency-assisted liver partition and portal vein ligation for staged hepatectomy (RALPPS)"and "Mini-ALPPS". These eponyms project hermetic competence and revive the long-lost optimism of aggressive cancer surgery in the age of genetics and targeted therapies.